Indications › Prediabetes
GLP‑1 drugs in prediabetes
Which incretin agents are being studied in prediabetes, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 32
- Active
- 9
- Results scheduled
- 3
- Molecules studied
- 6
- Sponsors
- 25
No GLP‑1 or incretin drug is FDA-approved for prediabetes. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.
No GLP-1 or incretin drug is approved for prediabetes, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 26 of the 32 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 6 still in early phases. 25 distinct sponsors are involved, 1 of the trials run commercially and the rest by universities and hospitals.
Molecules studied in this indication
exenatide · liraglutide in this indication · mazdutide · orforglipron · semaglutide in this indication · tirzepatide
Results due in this indication
| Est. completion | Drug | Trial | Phase | Participants |
|---|---|---|---|---|
| 2026-10-31 | semaglutide | Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes NCT05119179 · The University of Texas Health Science Center, Houston | P4 | 300 |
| 2027-12-15 | tirzepatide | Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide NCT06657209 · Stanford University | P4 | 104 |
| 2028-06 | mazdutide | Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) NCT07654062 · Shandong Provincial Hospital | P4 | 150 |
Trials on file
All 32 incretin trials recorded in this indication, active first.